Proteomics Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Proteomics Weekly


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Institute for Quality and Efficiency in Health Care

Benefit of memantine in the treatment of Alzheimer's disease not proven

There is no scientific proof that patients with moderate or severe Alzheimer's disease benefit from drugs containing the agent memantine. This is the conclusion in the final report that the Institute for Quality and Efficiency in Health Care (IQWiG) published in September 2009.

The report is part of a broader commission awarded by the Federal Joint Committee (G-BA) to assess both drug and non-drug therapy options for Alzheimer's disease. In addition to memantine, IQWiG has investigated cholinesterase inhibitors, Ginkgo biloba and non-drug therapy alternatives.

Memantine is intended to regulate...

• View Other Issues of Proteomics Weekly
  
• View Other NewsRx Publications